Patient No.	Broad-spectrum Antibiotics	Defective Skin Barrier	CRP(mg/dL)	WBC(10³/µL)	ANC(10³/µL)	ICU Admission	Mechanical Ventilation	Concomitant BSI	CVC Removal	Antibiotic Treatment	Total Duration of Treatment (days)	Survival *****	Follow-up (days)
1	No	Yes	3.5	8.2	0.7	No	No	No	No	Meropenem; moxifloxacin	14	Yes	2053
2	Yes	Yes	11.3	27.5	21.7	Yes	Yes	Yes1	Yes	TMP-SMX; meropenem;moxifloxacin; tigecyclin	20	Yes	395
3	Yes	No	25.5	0.2	0	Yes	Yes	No	No	Meropenem; fosfomycin;tigecyclin	45	No	45
4	No	No	19.8	0	0	Yes	No	No	No	Meropenem; ciprofloxacin	1	No	2
5	Yes	Yes	37.9	0.3	0	Yes	Yes	Yes2	Yes	TMP-SMX; meropenem	2	No	3
6	Yes	No	6.1	0.7	0.2	No	No	No	Yes	Ceftazidim; colistin; moxifloxacin; tigecyclin	18	Yes	167
7	Yes	No	23.0	0	0	No	No	No	Yes	Ceftazidim; colistin; moxifloxacin; tigecyclin	27	Yes	497
8	Yes	Yes	3.3	0	0	Yes	No	No	Yes	Meropenem; colistin;moxifloxacin; tigecyclin	10	No	10
9	Yes	No	9.7	0	0	No	No	No	Yes	Meropenem; ciprofloxacin	15	Yes	2446
10	Yes	Yes	15.2	23.3	18.0	Yes	Yes	Yes3	Yes	Ceftazidim; tobramycin	14	No	79

ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; BSI, blood stream infection; CRP, C-reactive protein; CVC, central venous catheter; DSP, desmoplakin; EwS, Ewing sarcoma; F, female; HCT, hematopoetic stem cell transplantation; HLH, hemophagocytic lymphohistiocytosis; ICU, intensive care unit; IST, immunosuppressive therapy; M, male; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; SCID, severe combined immunodeficiency; SM, Stenotrophomonas maltophilia; WBC, white blood cell count; VSAA, very severe aplastic anemia.

* Associated with recurrent infections, especially skin; care at the Department of Hematology and Oncology; * Conditions in allo-HCT recipients: Patient 1, chronic graft-versus-host disease (GVHD) of the skin, off immunosuppression, low dose steroids (< 0.3 mg/kg prednisone equivalent); patient 4, primary graft failure; patient 5, chronic GVHD of the skin and the gastrointestinal tract, immunosuppression with sirolimus, anti-inflammatory antibodies, methylprednisolone 2 mg/kg/d; patients 7 and 8 were prior to engraftment. ** including pulmonary hemorrhage (please see Figure 3 for details); * patient 1 had a catheter exit-site infection, and patient 8 had necrotizing fasciitis involving the lower extremities and buttocks. ** Four patients died in direct causal relationship to the infection from pulmonary hemorrhage (patients 3,4,5) and necrotizing fasciitis (patient 7) with multiorgan failure, and one patient (patient 10) died two months after completion of treatment from unrelated causes in hospice care.

¹ Staphylococcus hemolyticus, Staphylococcus aureus, Enterococcus faecalis and Candida albicans in the week prior to diagnosis of S.maltophilia infection and another blood culture positive for Staphylococcus hemolyticus in the week after; ² Escherichia coli, Enterococcus faecium, Staphylococcus epidermidis in the week prior to diagnosis of S.maltophilia infection; ³ Pseudomonas aeruginosa, Staphylococcus hemolyticus, and Enterococcus faecium in the week prior to diagnosis of S.maltophilia infection.